Mianserin, a 5-HT(2a/2c) and α2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors

Clinical Neuropharmacology

Volumn 20, Issue 3, 1997, Pages 210-214

  Aizenberg, Dov ^a,b   Gur, Shay ^a,b   Zemishlany, Zvi ^a,b   Granek, Michel ^a,b   Jeczmien, Pablo ^a,b   Weizman, Abraham ^a,b  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antidepressants; Cyproheptadine; Mianserin; Serotonin; Serotonin reuptake inhibitors; Sexual dysfunction; Yohimbine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; CLOMIPRAMINE; CYPROHEPTADINE; FLUOXETINE; FLUVOXAMINE; MIANSERIN; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; YOHIMBINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; SEROTONIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; HUMAN; MALE; OBSESSION; ORGASM; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SATISFACTION; SEXUAL DYSFUNCTION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MIDDLE AGED; PENIS ERECTION; PSYCHOSEXUAL DISORDER;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; HUMANS; MALE; MIANSERIN; MIDDLE AGED; ORGASM; PENILE ERECTION; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 0030611252     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199706000-00004     Document Type: Article

References (18)

1. Zajeka J, Fawcett J, Schaff M, Jeffriess H, Guy C. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991;52:66-8.
2. Sovner R. Treatment of tricyclic antidepressant-induced orgasmic inhibition with cyproheptadine. J Clin Psychopharmacol 1984;4:169.
3. Schiavi RE, Seglraves RT. The biology of sexual function. Psychiatr Clin North Am 1995;18:7-23.
4. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-22.
5. Aizenberg D, Zemishlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 1995;18:320-4.
6. Murphy DL, Mitchell PB, Potter WZ. Novel pharmacological approaches to the treatment of depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995;1143-53.
7. Burrows GD, Norman TR, Dennerstien L, Davies BM. Antidepressant therapy: benefits and risks in perspective. Acta Psychiatr Scand 1985;72(Suppl 320):43-7.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Press, 1994.
9. Endincott J, Spitzer RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978;35:837-44.
10. Feder R. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. J Clin Psychiatry 1991;52:163-4.
11. Goldbloom DS, Kennedy SH. Adverse interaction of fluoxetine by cyproheptadine in two patients with bulimia nervosa. J Clin Psychiatry 1991;52:261-2.
12. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
13. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5.
14. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): part I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11.
15. Argiolas A, Melis MR. Neuromodulation of penile erection: an overview of the role of neurotransmitters and neuropeptides. Prog Neurobiol 1995;47:235-55.
16. Segraves RT. Antidepressant-induced orgasm disorder. J Sex Marital Ther 1995;21:192-201.
17. Kanba S, Richelson E. Histamine H1 receptors in human brain labeled with [3H] doxepin. Brain Res 1984;304:1-7.
18. Pinder RM. Adrenoreceptor interactions of the enantiomers and metabolites of mianserin: are they responsible for the antidepressant effect? Acta Psychiatr Scand 1985;72(suppl 320):1-9.